A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors
Latest Information Update: 03 Jun 2024
At a glance
- Drugs M 701 (Primary)
- Indications Malignant ascites
- Focus Therapeutic Use
- Sponsors YZY Biopharma
Most Recent Events
- 03 Jun 2024 New trial record